Ignite Creation Date:
2024-07-17 @ 12:01 PM
Last Modification Date:
2024-10-26 @ 3:34 PM
Study NCT ID:
NCT06497985
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-07-12
First Post:
2024-06-28
Brief Title:
Phase III Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSSpMMR Colorectal Cancer Patients
Sponsor:
Chipscreen Biosciences Ltd
Organization:
Chipscreen Biosciences Ltd
Organization Data
Organization:
Chipscreen Biosciences Ltd
Class:
INDUSTRY
Study ID:
CDM303
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Chipscreen Biosciences Ltd
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None